Search Result
Results for "
NLRP3 Inhibitor
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-144226
-
|
|
NOD-like Receptor (NLR)
AIM2
Pyroptosis
|
Inflammation/Immunology
|
|
NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC50 of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization .
|
-
-
- HY-162333
-
-
-
- HY-150206
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
|
NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM). NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders .
|
-
-
- HY-157146
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-23 (Compound 15C) is an inhibitor of heme-mediated induction of the NLRP3 inflammasome. NLRP3-IN-23 significantly inhibits heme-mediated induction of the NLRP3 inflammasome at a concentration of 0.1 μM .
|
-
-
- HY-N12482
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-27 (compound 1) is an inhibitor of NLRP3 with an IC50 value of 0.74 μM. NLRP3 reduces inflammasome-induced pyroptosis in J774A.1 cells. NLRP3-IN-27 can be isolated from Callicarpa arborea Rox .
|
-
-
- HY-161120
-
-
-
- HY-164765
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-56 (compound 062) is a NLRP3 inhibitor. NLRP3-IN-56 potently inhibits the level of IL-1β secretion by THP-1 cells with an IC50 of 9.7 nM. NLRP3-IN-56 can be used for the study of NLRP3-mediated symptoms and/or diseases .
|
-
-
- HY-161266
-
-
-
- HY-158024A
-
-
-
- HY-159482
-
|
|
Cholinesterase (ChE)
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC50 values of are 0.37, 0.31, 0.29 μM respectively, and the EC50 of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research .
|
-
-
- HY-162901
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
NLRP3-IN-48 is an NLRP3 inhibitor. NLRP3-IN-48 targets the NLRP3 protein, affecting the assembly of the NLRP3 inflammasome and thereby inhibiting its activation. NLRP3-IN-48 has anti-inflammatory activity in a mouse model of acute colitis induced by DSS .
|
-
-
- HY-145911
-
-
-
- HY-157147
-
-
-
- HY-146802
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-9 is a potent NLRP3 inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout .
|
-
-
- HY-149604
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .
|
-
-
- HY-149122
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-15 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-15 inhibits IL-1β release with an IC50 of 0.114 μM. NLRP3-IN-15 can be used for the research of inflammation .
|
-
-
- HY-149123
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-16 is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-16 inhibits IL-1β release with an IC50 of 0.065 μM. NLRP3-IN-16 can be used for the research of inflammation .
|
-
-
- HY-151952
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC50 of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease .
|
-
-
- HY-162980
-
-
-
- HY-162846
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-44 (compound P33) is a potent and orally active (approximately 62%) inhibitor of NLRP3, with the Kd of 17.5 nM. NLRP3-IN-44 plays an important for studying NLRP3 inflammasome-mediated diseases .
|
-
-
- HY-168009
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-45 (D6) is an inhibitor of NLRP3 inflammasome activation, inhibiting the activity of IL-1β (IC50=41.79 nM). NLRP3-IN-45 exerts its effects without affecting the initial stage of NLRP3 inflammasome activation. NLRP3-IN-45 specifically inhibits the activation of NLRP3 inflammasome in the LPS-induced acute lung injury (ALI) mouse model .
|
-
-
- HY-163497
-
-
-
- HY-169227
-
|
|
Pyroptosis
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-55 (Compound 19) is a potent NLRP3 inhibitor (IC50 = 0.34 μM). NLRP3-IN-55 directly targets the NLRP3 protein (KD = 0.45 μM), blocking the assembly and activation of the NLRP3 inflammasome, leading to anti-inflammatory effects and inhibition of cellular pyroptosis .
|
-
-
- HY-149121
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-14 is a potent and selective NLRP3 inflammasome inhibitor (KD: 5.87 μM). NLRP3-IN-14 inhibits IL-1β release with an IC50 of 0.131 μM. NLRP3-IN-14 can be used for the research of inflammation .
|
-
-
- HY-163179
-
-
-
- HY-145910
-
-
-
- HY-158111
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis .
|
-
-
- HY-153261
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC50 value of 7 nM. NLRP3-IN-17 significantly inhibits NLRP3 dependent IL-1β secretion in mice and can be used for chronic inflammatory diseases research .
|
-
-
- HY-163493
-
-
-
- HY-163494
-
-
-
- HY-162992
-
-
-
- HY-103666
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
|
-
-
- HY-162013
-
-
-
- HY-163756
-
-
-
- HY-155463
-
|
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
|
NLRP3-IN-25 (compound 32) is an orally available NLRP3 inhibitor with anti-inflammatory activity. NLRP3-IN-25 attenuates renal injury in doxorubicin-induced glomerulonephritis in mice. NLRP3-IN-25 inhibits IL-1β secretion in THP-1 cells with an IC50 of 21 nM .
|
-
-
- HY-163300
-
-
-
- HY-132892
-
-
-
- HY-163695
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research .
|
-
-
- HY-157555
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
NLRP3-IN-29(Compound 5M) is an inhibitor of NLR family pyrin domain containing 3 (NLRP3). NLRP3-IN-29 has the potential for blood-brain barrier permeability and inflammation inhibition both in vivo and in vitro. NLRP3-IN-29 can be used for research on Alzheimer's disease .
|
-
-
- HY-161669
-
-
-
- HY-148187
-
|
|
NOD-like Receptor (NLR)
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases .
|
-
-
- HY-163744
-
-
-
- HY-W011082R
-
|
|
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
|
NLRP3-IN-2 (Standard) is the analytical standard of NLRP3-IN-2. This product is intended for research and analytical applications. NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
|
-
-
- HY-153554
-
-
-
- HY-160545
-
-
-
- HY-163498
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
|
NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .
|
-
-
- HY-156469
-
-
-
- HY-168089
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-49 (compound Z48) is a potent and specific NLRP3 inhibitor (IC50=0.26 μM in THP-1 cells, IC50=0.21 μM in mouse bone marrow macrophages). NLRP3-IN-49 can directly bind to NLRP3 protein (Kd=1.05 μM), effectively preventing the assembly and activation of NLRP3 inflammasome, thereby exhibiting anti-inflammatory properties. NLRP3-IN-49 can be used in the study of inflammatory bowel disease .
|
-
-
- HY-169188
-
|
|
NOD-like Receptor (NLR)
|
Cancer
|
|
NLRP3-IN-50 (compound SN3-1) is a potential NLRP3 inhibitor with therapeutic potential for inflammatory diseases. .
|
-
-
- HY-B0466
-
|
|
Beta-lactamase
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
|
-
- HY-B0466B
-
-
- HY-B0466A
-
-
- HY-161072
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC50 value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models .
|
-
- HY-168503
-
-
- HY-156034
-
|
NLRP3-IN-19
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
|
-
- HY-156034A
-
|
NLRP3-IN-19 sodium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .
|
-
- HY-161329
-
|
|
NOD-like Receptor (NLR)
Reactive Oxygen Species
NF-κB
IKK
|
Inflammation/Immunology
|
|
NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation of IκBα and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting NF-κB signaling .
|
-
- HY-156121
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
NLRP3-IN-20 (compound 11) is an orally available inhibitor of the NLRP3 inflammasome with an IC50 of 25 nM for IL-1β secretion. NLRP3-IN-20 has excellent pharmacokinetic properties and demonstrated significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis .
|
-
- HY-168594
-
|
|
Glycosidase
NOD-like Receptor (NLR)
|
Neurological Disease
Metabolic Disease
|
|
α-Glucosidase/NLRP3-IN-1 (Compound 8) is a dual inhibitor of α-glucosidase and NLRP3, exhibiting an IC50 of 6.6 μM against α-glucosidase and inhibiting NLRP3 in multiple cell lines at a concentration of 100 μM. α-Glucosidase/NLRP3-IN-1 demonstrates neuroprotective and antidiabetic properties, and can be utilized in relevant research .
|
-
- HY-132831
-
|
Somalix; RO-7486967; IZD334
|
NOD-like Receptor (NLR)
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease
|
-
- HY-159719
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
NLRP3-IN-51 (Compound 3q) is a potent cholinergic anti-inflammatory pathway (CAP) activators. ANLRP3-IN-51 inhibits Monosodium urate (MSU) (HY-B2130A)-induced IL-1β production in THP-1 cells, indicating its potential against gout arthritis. NLRP3-IN-51 inhibits MSU induced phosphorylation of NF-κB p65, without any inhibitory effect against NLRP3, pro-caspase 1, or the self-cleavage and activation of caspase-1 of the second signaling. Therefore, NLRP3-IN-51 inhibits the initial phase of NLRP3 through CAP activation .
|
-
- HY-159718
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-46 (Compound 3k) activates neuro-immunomodulatory cholinergic anti-inflammatory pathway, and thus inhibits NLRP3 inflammasome activation. NLRP3-IN-46 inhibits Uric acid sodium (HY-B2130A)-induced IL-1β production in THP-1 cells, and can be used in gouty arthritis research .
|
-
- HY-168561
-
-
- HY-W011082
-
|
|
NOD-like Receptor (NLR)
|
Cardiovascular Disease
|
|
NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
|
-
- HY-168520
-
-
- HY-146594
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-8 (compound 27) is an orally active, directly binding NLRP3 inflammasome inhibitor with an IC50 value of 1.23 μM against IL-1 β. NLRP3-IN-8 has good metabolic stability to liver microsomes (t1/2 = 138.63 min), and has almost no toxicity (against L02: IC50 > 100 μM) .
|
-
- HY-B0466R
-
|
|
Beta-lactamase
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Cloxacillin (sodium monohydrate) (Standard) is the analytical standard of Cloxacillin (sodium monohydrate). This product is intended for research and analytical applications. Cloxacillin sodium monohydrate is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium monohydrate can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
|
-
- HY-B0466BR
-
|
|
Beta-lactamase
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Cloxacillin (sodium) (Standard) is the analytical standard of Cloxacillin (sodium). This product is intended for research and analytical applications. Cloxacillin sodium is an orally active antibacterial agent and β-lactamase inhibitor with an IC50 of 0.04 μM. Cloxacillin sodium can suppress the S. aureus-induced inflammatory response by inhibiting the activation of MAPKs, NF-кB and NLRP3-related proteins .
|
-
- HY-149478
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
JT002 is an orally active inhibitor of the NLRP3 inflammasome. JT002 reduces NLRP3-dependent proinflammatory cytokine (such as IL-1β, IL-1α, IL-18) production and pyroptosis. JT002 blocks NLRP3 inflammasome complex formation. JT002 reduces airway hyperresponsiveness and airway neutrophilia in mice .
|
-
- HY-101868
-
-
- HY-131040
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca 2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .
|
-
- HY-162877
-
-
- HY-145087
-
-
- HY-N9921
-
|
|
Pyroptosis
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .
|
-
- HY-157554
-
-
- HY-144223
-
|
|
NOD-like Receptor (NLR)
AIM2
|
Inflammation/Immunology
|
|
NLRP3/aim2-in-2 (compound 8) is a new potent inhibitor with different species-specific effects on NLRP3 and AIM2 inflammasome dependent cell death. Its < b > IC < sub > 50 < / sub > < / b > value is 0.2392 ± 0.0233 μ M。
|
-
- HY-121988
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction .
|
-
- HY-169996
-
-
- HY-163358
-
-
- HY-158093
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NIC-12 is a potent NLRP3 inhibitor. NIC-12 selectively reduces circulating IL-1ß levels in the LPS-endotoxemia mice model. NIC-12 inhibits NLRP3 inflammasome activation in mouse macrophages .
|
-
- HY-162402
-
|
|
Reactive Oxygen Species
Cholinesterase (ChE)
|
Cancer
|
|
NLRP3-IN-33 (Compound 12o) is a blood-brain barrier permeable inhibitor of AChE and BChE, with IC50 values of 1.02 μM and 7.03 μM against hAChE and hBChE respectively. NLRP3-IN-33 possesses antioxidant, anti-inflammatory, and metal chelating activities, making it a potential candidate for research in Alzheimer's disease (AD) .
|
-
- HY-168737
-
|
|
NOD-like Receptor (NLR)
NEKs
|
Inflammation/Immunology
|
|
NEK7-IN-2 (compound 23) is a potent inhibitor of NLRP3-NEK7 interaction. NEK7-IN-2 can enhance the thermal stability of NEK7 and regulatie NLRP3 inflammasome assembly. NEK7-IN-2 inhibits IL-1β releases .
|
-
- HY-144220
-
-
- HY-164304
-
-
- HY-120007
-
-
- HY-161297
-
-
- HY-156374
-
|
|
NOD-like Receptor (NLR)
Pyroptosis
|
Inflammation/Immunology
|
|
D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice .
|
-
- HY-148258
-
-
- HY-162150
-
|
AZL-N
|
Pyroptosis
|
Inflammation/Immunology
|
|
Azalamellarin N is an inhibitor of pyroptosis and has different inhibitory effects on different pyroptosis inducers. Azalamellarin N inhibits pyroptosis by targeting molecules that act upstream of NLRP3 inflammasome activation, rather than directly targeting components of the NLRP3 inflammasome. Inhibitory potency against different pyroptosis inducers: Nigericin (HY-127019) > R837 (HY-B0180) .
|
-
- HY-N10359
-
-
- HY-161297A
-
-
- HY-N3005
-
|
|
Apoptosis
Autophagy
NOD-like Receptor (NLR)
Pyroptosis
|
Inflammation/Immunology
Cancer
|
|
Britannin is an NLRP3 inhibitor with an IC50 of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the NLRP3 inflammasome by blocking the interaction between NLRP3 and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics .
|
-
- HY-137245
-
|
MCC7840
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Emlenoflast (MCC7840), a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. Emlenoflast can be used for the research of inflammatory diseases .
|
-
- HY-137245A
-
|
MCC7840 sodium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Emlenoflast (MCC7840) sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. Emlenoflast sodium can be used for the research of inflammatory diseases .
|
-
- HY-111662
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis .
|
-
- HY-119721
-
-
- HY-12815A
-
MCC950 sodium
Maximum Cited Publications
296 Publications Verification
CP-456773 sodium; CRID3 sodium salt
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
|
-
- HY-12815
-
-
- HY-120920
-
|
|
Dopamine Receptor
|
Inflammation/Immunology
|
|
UNC9995 is a β-arrestin2-biased agonist of dopamine receptor Drd2. UNC9995 inhibits NLRP3 inflammasome activation by enhancing β-arrestin2-NLRP3 interaction, thus prevents neuronal degeneration. Futhermore, UNC9995 activates the Drd2/β-arrestin2 signaling to prevent inflammation-related genes transcription-induced by JAK/STAT3. UNC9995 improves depressive behavior in mouse model, and improves astrocytes dysfunctions .
|
-
- HY-N0373
-
|
|
Amyloid-β
Apoptosis
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
|
-
- HY-130494
-
-
- HY-N12941
-
-
- HY-155517
-
|
|
NOD-like Receptor (NLR)
Pyroptosis
|
Inflammation/Immunology
|
|
INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation .
|
-
- HY-W923189
-
-
- HY-17629
-
|
OLT1177
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
Cancer
|
|
Dapansutrile is a potent, orally active and selective NLRP3 inflammasome inhibitor. Dapansutrile has anti-inflammatory activity and decreases immune factor levels. Dapansutrile can be used for research of inflammatory diseases .
|
-
- HY-158155
-
-
- HY-N0373R
-
|
|
Amyloid-β
Apoptosis
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
Licochalcone B (Standard) is the analytical standard of Licochalcone B. This product is intended for research and analytical applications. Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction .
|
-
- HY-120048
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NBC19 is an NLRP3 inflammasome inhibitor with an IC50 of 60 nM in differentiated THP1 cells. NBC19 inhibits nigericin- and ATP-induced IL-1β release with IC50s of 80 nM and 850 nM, respectively .
|
-
- HY-B0004
-
|
|
Adenosine Receptor
Phosphodiesterase (PDE)
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
|
-
- HY-W1000105
-
-
- HY-163159
-
-
- HY-P2275B
-
-
- HY-132831B
-
|
Somalix potassium; RO-7486967 potassium; IZD334 potassium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Selnoflast (RO-7486967) Potassium, formerly Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in the study of systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease .
|
-
- HY-139667
-
|
|
Pyruvate Kinase
|
Neurological Disease
|
|
PKM2-IN-3 is an inhibitor of PKM2 kinase with an IC50 value of 4.1 μM. PKM2-IN-3 exhibits an anti-neuroinflammatory effect by inhibiting PKM2-mediated glycolysis and NLRP3 activation .
|
-
- HY-156798
-
ADS032
1 Publications Verification
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
|
ADS032 is a sulfonylurea compound that is an NLRP1 and NLRP3 inflammasome inhibitor. ADS032 reduces the secretion of inflammatory factors and inhibits the oligomerization of ASC. ADS032 has anti-inflammatory effects in a variety of inflammatory models and can be used in the study of inflammatory diseases .
|
-
- HY-159159
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .
|
-
- HY-117432
-
-
- HY-150965
-
|
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity .
|
-
- HY-168264
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
MC1 is a potent NLRP3 inhibitor with a KD value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD) .
|
-
- HY-16059
-
|
(+)-Arglabin
|
NOD-like Receptor (NLR)
Farnesyl Transferase
Autophagy
|
Inflammation/Immunology
Cancer
|
|
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities . The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene .
|
-
- HY-145087A
-
-
- HY-B0006A
-
|
BM 14190 phosphate hemihydrate
|
Adrenergic Receptor
Autophagy
Bacterial
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker . Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
- HY-B0004R
-
|
|
Adenosine Receptor
Phosphodiesterase (PDE)
Reactive Oxygen Species
|
Inflammation/Immunology
|
|
Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm .
|
-
- HY-N0633
-
-
- HY-132831A
-
|
Somalix calcium; RO-7486967 calcium; IZD334 calcium
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Selnoflast (RO-7486967) calcium Formerly known as Somalix/RG6418/IZD334, Selnoflast is an orally available inhibitor of NLRP3. Selnoflast is used in the study of systemic inflammation, such as ulcerative colitis and chronic obstructive pulmonary disease[1]/s.br/ .
|
-
- HY-B0006
-
-
- HY-137888A
-
|
oATP trisodium salt
|
P2X Receptor
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. Oxidized ATP trisodium salt irreversibly antagonizes P2X7R activation. Oxidized ATP trisodium salt inhibits c-reactive protein (CRP)-induced NLRP3 inflammasome activation. Oxidized ATP trisodium salt can be used for research of atherosclerosis .
|
-
- HY-137387
-
|
|
Drug Metabolite
|
Cardiovascular Disease
Others
|
|
Carvedilol Glucuronide is the metabolite of Carvedilol (HY-B0006). Carvedilol (BM 14190) is an antagonist for β/α-1 adrenergic receptor. Carvedilol inhibits lipid peroxidation with an IC50 of 5 μM. Carvedilol is an antihypertensive agent with potential use in angina and congestive heart failure. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
- HY-14644B
-
|
STA 5326 hydrochloride; LAM-002A (free base) hydrochloride; AIT-101 hydrochloride
|
NOD-like Receptor (NLR)
|
Infection
Inflammation/Immunology
|
|
Apilimod (STA 5326) hydrochloride is a PIKFYVE kinase inhibitor that promotes NLRP3 inflammatory vesicle activation and IL-1β secretion. Apilimod hydrochloride has been shown to inhibit host cell proteases, which may prevent viral invasion but also block antiviral immune responses, potentially exacerbating immunosuppression in COVID-19.
|
-
- HY-B0116
-
-
- HY-B0116A
-
-
- HY-169018
-
-
- HY-146765
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
|
AMS-17 is a potent NLRP3 inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders .
|
-
- HY-151252
-
|
|
Proteasome
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β .
|
-
- HY-168091
-
|
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
|
YM-I-26 is a selective NLRP3 inflammasome inhibitor. YM-I-26 enhances the phagocytosis of β-amyloid protein by mouse microglial BV2 cells and inhibits the production of IL-1β and IL-10. YM-I-26 can be used to study the immunomodulatory activity associated with inflammation .
|
-
- HY-155753
-
|
|
NF-κB
COX
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 50 (compound a1) is a Fusidic acid derivative with anti-inflammatory effects. Anti-inflammatory agent 50 inhibits inflammatory factor NO, IL-6 and TNF-α. Anti-inflammatory agent 50 alleviates acute lung injury by regulating inflammatory mediators and suppressing the MAPK, NF-κB and NLRP3 inflammasome signaling pathways .
|
-
- HY-158024
-
|
|
NOD-like Receptor (NLR)
|
Neurological Disease
|
|
NDT-19795 is an effective inhibitor of the NLRP3 inflammasome with an IC50 value of 66 nM in the PBMC method and 4.7 μM in the WB method. NDT-19795 is a carboxylic acid-active substance that can be converted from NT-0796 (HY-156438) within cells. NDT-19795 can be used for the study of neurological diseases .
|
-
- HY-122920
-
|
|
HSV
CMV
Influenza Virus
HIV
NOD-like Receptor (NLR)
YB-1
|
Infection
Inflammation/Immunology
|
|
Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication. Soyasaponin II serves as a inhibitor for YB-1 phosphorylation and NLRP3 inflammasome priming and could protect mice against LPS/GalN induced acute liver failure .
|
-
- HY-N0633R
-
-
- HY-B0006R
-
|
BM 14190 (Standard)
|
Adrenergic Receptor
Autophagy
Bacterial
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Carvedilol (Standard) is the analytical standard of Carvedilol. This product is intended for research and analytical applications. Carvedilol (BM 14190) is a non-selective β/α-1 blocker . Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure . Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome .
|
-
- HY-B0780
-
-
- HY-N0408
-
-
- HY-N0743
-
-
- HY-161155
-
|
|
HDAC
|
Inflammation/Immunology
|
|
HDAC6-IN-31 (compound 8m) is a selective HDAC6 inhibitor, with the IC50 value of 0.026 μM, that significantly inhibits the production and release of pro-inflammatory cytokines. While HDAC6 is critically involved in the activation of inflammasomes, HDAC6-IN-31 has the potential to inhibit NLRP3 inflammasome-driven inflammatory diseases. HDAC6-IN-31 also inhibits glioblastoma cell migration .
|
-
- HY-B0116R
-
|
|
Reverse Transcriptase
HIV
Nucleoside Antimetabolite/Analog
NOD-like Receptor (NLR)
Autophagy
Apoptosis
|
Infection
|
|
Stavudine (Standard) is the analytical standard of Stavudine. This product is intended for research and analytical applications. Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis .
|
-
- HY-NP135
-
|
Human ox-LDL
|
NO Synthase
NOD-like Receptor (NLR)
|
Metabolic Disease
Inflammation/Immunology
|
|
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
|
-
- HY-16569
-
|
|
Microtubule/Tubulin
NOD-like Receptor (NLR)
Autophagy
Apoptosis
|
Cancer
|
|
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
|
-
- HY-155751
-
-
- HY-144765
-
|
|
NF-κB
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
|
NF-κB-IN-4 (compound 17) is a potent and BBB-penetrated NF-κB pathway inhibitor with blood brain barrier (BBB) permeability. NF-κB-IN-4 exhibits potential anti-neuroinflammatory activity with low toxicity. NF-κB-IN-4 can block the activation and phosphorylation of IκBα, reduce expression of NLRP3, and thus inhibit NF-κB activation. NF-κB-IN-4 can be used for neuroinflammation related diseases research .
|
-
- HY-N0194
-
|
|
Apoptosis
Parasite
|
Inflammation/Immunology
Cancer
|
|
Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model .
|
-
- HY-130252
-
YQ128
1 Publications Verification
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
|
YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity . YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-16569R
-
|
|
Microtubule/Tubulin
NOD-like Receptor (NLR)
Autophagy
Apoptosis
|
Cancer
|
|
Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
|
-
- HY-144634
-
|
|
Keap1-Nrf2
|
Neurological Disease
Inflammation/Immunology
|
|
DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD) .
|
-
- HY-163909
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
AChE-IN-72 (Compound 13a) is an inhibitor for acetylcholinesterase (AChE) with an IC50 of 0.59 μM. AChE-IN-72 inhibits BChE with an IC50 of 5.02 μM. AChE-IN-72 exhibits radical scavenging with IC50 of 5.88 μM. AChE-IN-72 exhibits iron-chelating property, inhibits Aβ1−42 aggregation, and inhibits NLRP3 inflammasome activation. AChE-IN-72 ameliorates memory impairment in Betaine (HY-B0710)-induced AD mouse model. AChE-IN-72 is blood-brain barrier (BBB) penetrable .
|
-
- HY-N0194R
-
|
|
Apoptosis
Parasite
|
Inflammation/Immunology
Cancer
|
|
Asiatic acid (Standard) is the analytical standard of Asiatic acid. This product is intended for research and analytical applications. Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model .
|
-
- HY-161627
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
Anemoside A3-methyl 6-aminohexanoate (Compound A3-6) is a derivative of Pulchinenoside C (Anemoside B4) (HY-N0205). Anemoside A3-methyl 6-aminohexanoate inhibits pyruvate carboxylase (PC) with an IC50 of 0.058 μM, reprograms macrophage function, and alleviates DSS-induced colitis through inhibition of the NF-κB and NLRP3 inflammasome pathway. Anemoside A3-methyl 6-aminohexanoate exhibits a moderate in vivo pharmacokinetic characters compared with Anemoside B4 .
|
-
- HY-156438
-
|
|
NOD-like Receptor (NLR)
Interleukin Related
|
Neurological Disease
|
|
NT-0796 is an orally active, selective and CNS-penetrant NLRP3 inflammasome inhibitor. NT-0796 inhibits IL-1β release in human PBMC cells with an IC50 value of 0.32 nM. NT-0796 is an isopropyl ester that undergoes intracellular conversion to NDT-19795, the carboxylic acid active species. NT-0796 reverses high fat diet-induced obesity, systemic inflammation and astrogliosis in the diet-induced obesity mouse model. NT-0796 is promising for research of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis .
|
-
- HY-159898
-
|
|
Cholinesterase (ChE)
Amyloid-β
Tau Protein
NOD-like Receptor (NLR)
Reactive Oxygen Species
Mitochondrial Metabolism
|
Neurological Disease
|
|
AChE/BChE-IN-23 (Compound 6e) is an AChE/BChE inhibitor (IC50: 0.91 μM, 1.19 μM and 1.01 μM for hAChE, eq BChE and hBChE, respectively). AChE/BChE-IN-23 has antioxidant activity and inhibits Aβ1-42 and Tau protein aggregation. AChE/BChE-IN-23 also inhibits microglial activation by reducing ROS release and mitochondrial injury. AChE/BChE-IN-23 suppresses NLRP3 inflammasome and pro-inflammatory cytokines in human microglial cells. AChE/BChE-IN-23 also reverses the Scopolamine (HY-N0296)-induced memory impairment in mice model .
|
-
- HY-N0408R
-
|
|
NF-κB
Reactive Oxygen Species
Apoptosis
Influenza Virus
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Picroside II (Standard) is the analytical standard of Picroside II. This product is intended for research and analytical applications. Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities.
picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of NLRP3 inflammasome and NF-κB pathways .
Picroside II is an antioxidant, exhibits a significant neuroprotective effect through reducing ROS production and protects the blood-brain barrier (BBB) after cerebral ischemia-reperfusion (CI/R) injury. Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities .
|
-
- HY-156150
-
|
|
Fungal
Cytochrome P450
PD-1/PD-L1
|
Infection
|
|
CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
|
-
- HY-156151
-
|
|
Fungal
Cytochrome P450
PD-1/PD-L1
|
Infection
|
|
CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
|
-
- HY-156149
-
|
|
Fungal
Cytochrome P450
PD-1/PD-L1
|
Infection
|
|
CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
|
-
- HY-Y0148
-
|
NSC 15139; 10-HDAA
|
Parasite
Autophagy
NF-κB
Interleukin Related
NO Synthase
MDM-2/p53
TNF Receptor
RANKL/RANK
Caspase
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-NP135
-
|
Human ox-LDL
|
Native Proteins
|
|
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
|
| Cat. No. |
Product Name |
Target |
Research Area |
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N3005
-
-
-
- HY-N0373
-
-
-
- HY-16059
-
-
-
- HY-N0633
-
-
-
- HY-122920
-
-
-
- HY-N12482
-
-
-
- HY-N9921
-
-
-
- HY-N10359
-
-
-
- HY-N12941
-
-
-
- HY-N0373R
-
-
-
- HY-N0633R
-
-
-
- HY-N0408
-
-
-
- HY-N0743
-
-
-
- HY-16569
-
-
-
- HY-N0194
-
-
-
- HY-16569R
-
|
|
Structural Classification
Natural Products
other families
Source classification
Plants
|
Microtubule/Tubulin
NOD-like Receptor (NLR)
Autophagy
Apoptosis
|
|
Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
|
-
-
- HY-N0194R
-
|
|
Triterpenes
Structural Classification
Terpenoids
Source classification
Tagetes lucida Cav.
Umbelliferae
Plants
|
Apoptosis
Parasite
|
|
Asiatic acid (Standard) is the analytical standard of Asiatic acid. This product is intended for research and analytical applications. Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model .
|
-
-
- HY-N0408R
-
|
|
Structural Classification
Iridoids
Terpenoids
Scrophulariaceae
Plants
Picrorhiza scrophulariiflora Pennell
|
NF-κB
Reactive Oxygen Species
Apoptosis
Influenza Virus
|
|
Picroside II (Standard) is the analytical standard of Picroside II. This product is intended for research and analytical applications. Picroside II, an iridoid compound extracted from Picrorhiza, exhibits anti-inflammatory and anti-apoptotic activities.
picroside II alleviates the inflammatory response in sepsis and enhances immune function by inhibiting the activation of NLRP3 inflammasome and NF-κB pathways .
Picroside II is an antioxidant, exhibits a significant neuroprotective effect through reducing ROS production and protects the blood-brain barrier (BBB) after cerebral ischemia-reperfusion (CI/R) injury. Picroside II has antioxidant, anti-inflammatory, immune regulatory, anti-virus and other pharmacological activities .
|
-
-
- HY-Y0148
-
|
NSC 15139; 10-HDAA
|
Structural Classification
Animals
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Inflammation/Immunology
Disease Research Fields
|
Parasite
Autophagy
NF-κB
Interleukin Related
NO Synthase
MDM-2/p53
TNF Receptor
RANKL/RANK
Caspase
|
|
10-Hydroxydecanoic acid (10-HDAA) is a saturated fatty acid derived from 10-hydroxy-trans-2-decenoic acid, which can be isolated from royal jelly. 10-Hydroxydecanoic acid exhibits various biological activities, including anti-inflammatory, insecticidal, anti-malarial, and anti-Leishmania properties, as well as enhancing antigen-specific immune responses. The anti-inflammatory effects of 10-Hydroxydecanoic acid are primarily mediated by inhibiting the activation of NF-κB and the translation of interferon regulatory factor 1 (IRF-1), which reduces the production of interleukin 6 (IL-6) and nitric oxide (NO) in inflammatory cells. Additionally, 10-Hydroxydecanoic acid alleviates neuroinflammatory responses through the p53-autophagy pathway and the p53-NLRP3 pathway. Finally, 10-Hydroxydecanoic acid enhances antigen-specific immune responses by promoting the effective uptake of antigens by microfold cells .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-130252
-
YQ128
1 Publications Verification
|
|
Alkynes
|
|
YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity . YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-159159
-
|
|
|
Alkynes
|
|
MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
